Racemate Praziquantel ODT
Phase 2Small molecule
Merck & Co.Racemate Praziquantel ODT is one of 12 small molecule programs targeting Schistosomiasis. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Schistosomiasis
#DrugCompanyPhaseTrials
1Biltricide
BayerApproved
Artesunate
AAmivas Inc.
Approved
Daraprim
FFondazione Matilde Tettamanti Menotti De Marchi Onlus
Approved
Artesunate-Mefloquine
NovartisPhase 3
Selenium
SSWOG Cancer Research Network
Phase 2
GLA-SE
Merck & Co.Phase 2
Biltricide
Merck & Co.Phase 2
Sm14
OOswaldo Cruz Foundation
Phase 2
Racemate Praziquantel ODT
Merck & Co.Phase 2
Artesunate-Pyronaridine
CCentre de Recherche Médicale de Lambaréné
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Racemate Praziquantel ODT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company